Alberto Jose Montero MD MBA, CPHQ

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Clinical Director Breast Cancer Program UH/Seidman Cancer Center at University Hospitals

UH Cleveland Medical Center11100 Euclid Ave Department of Medicine-Hematology and OncologyCleveland, OH 44106
Phone+1 216-844-3951
Fax+1 216-844-5234

Dr. Montero is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Montero's full profile Already have an account?

Education & Training

Case Western Reserve UniversityMPOD, Organizational Development , 2024 - 2026
University of Miami School of BusinessMBA, 2011 - 2013
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1999 - 2002
University of Texas Medical Branch School of MedicineClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2008 - 2028
GA State Medical License 2026 - 2028
OH State Medical License 2013 - 2028
DE State Medical License 2025 - 2027
OR State Medical License 2026 - 2027
SC State Medical License 2005 - 2027
TX State Medical License 2002 - 2027
IL State Medical License 2025 - 2026
PA State Medical License 2025 - 2026
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Clinical Director, Breast Cancer Medical Oncology Program University Hospitals, 2020
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Start of enrollment: 2007 Jun 04
COMPLETED
PHASE2
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
COMPLETED
PHASE2
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
COMPLETED
PHASE2

Publications & Presentations

PubMed

Genomic risk distribution, adjuvant chemotherapy trends, and survival outcomes in women with pT1, grade 1-2, ER/PR-positive, LVI-negative breast cancer.
Nickolas Stabellini, Maya Lubarsky, Ananya Munjal, Amanda L Amin, Megan E Miller
Current Problems in Cancer. 2026-08-01
Prognostic consistency of oncotype DX® molecular assay across racial groups in early-stage hormone receptor-positive breast cancer.
Reine Abou Zeidane, Benjamin Hauk, Samuel Lichtman-Mikol, Courtney Pisano, Yilun Sun
NPJ Breast Cancer. 2026-06-25
Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer.
Nickolas Stabellini, Sonia D de Oliveira, Takae Mizukami, Shawn M Sweeney, Nikolaus Schultz
Breast Cancer Research. 2026-06-20

Journal Articles

Re: Xie, J, Diener M, De G et al Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative...
Diaby V, Adunlin G, Montero AJ, J Med Econ, 2/10/2014
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L
Diaz-Montero CM, Zidan AA, Pallin MF, Anagnostopoulos V, Salem ML, Wieder E, Komanduri K, Montero AJ , Lichtenheld MG, Immunol Res, 11/12/2013
Breast Cancer Survival Poorer in Black Women: Commentary
Montero AJ, Healio/HemOnc Today, 8/1/2013

Authored Content

Everywhere Winds: Pandemic Haiku for the SpiritMarch 2022
We Don't Have All the Answers, and We Don't Have ToMay 2021

Press Mentions

21 Oncology Leaders on the Innovations Transforming Breast Cancer CareOctober 29th, 2025
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast CancerDecember 10th, 2024
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab Will Be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024November 1st, 2024